Latest Breaking News On - Cyte contacts - Page 3 : vimarsana.com

MaxCyte to Report Fourth Quarter and Full Year 2023

ROCKVILLE, Md., Feb. 09, 2024 (GLOBE NEWSWIRE) MaxCyte, Inc., (NASDAQ: MXCT; LSE: MXCT), a leading, cell-engineering focused company providing.

United kingdomPanmure gordonDavid deuchlerRupert deardenMary jane elliottEmma earl freddy crossleyChris welshDigital healthGilmartin groupMaxcyte incLife scienceDiagnostic toolsAnnual cowen healthcareCyte contactsJoint corporateFreddy crossley

MaxCyte to Report Fourth Quarter and Full Year 2023 Financial Results on March 12, 2024 and Participate in Upcoming Investor Conferences

ROCKVILLE, Md., Feb. 09, 2024 MaxCyte, Inc., , a leading, cell-engineering focused company providing enabling platform technologies to advance the discovery, development and commercialization of.

United kingdomChris welshEmma earl freddy crossleyRupert deardenMary jane elliottDavid deuchlerPanmure gordonMaxcyte incDigital healthGilmartin groupLife scienceDiagnostic toolsAnnual cowen healthcareCyte contactsJoint corporateFreddy crossley

MaxCyte and Wugen Sign Strategic Platform License to Expedite Scale-Up of Clinical and Commercial Manufacturing of Wugen s Investigational Allogeneic, Off-the-Shelf Cell Therapies for Cancers -January 30, 2024 at 08:06 am EST

Wugen to use MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support its programs for hematologic and solid tumor cancersROCKVILLE, Md. and ST. LOUIS, Jan. 30, 2024 .

United kingdomMary jane elliottMark lewisPanmure gordonDavid deuchlerChris welshRupert deardenKumar srinivasanMaher masoudEmma earl freddy crossleyChristine fanelleMaxcyte incDrug administrationWugen incGilmartin groupFlow electroporation

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

Imugene using MaxCyte’s Flow Electroporation® technology and ExPERT™ platform to support azer-cel – a potential first-in-class allogeneic CD19 CAR T product candidate for the treatment of blood.

United kingdomNorth carolinaUnited statesWestern australiaNew south walesMary jane elliottPanmure gordonRupert deardenDavid deuchlerChris welshMatt wrightMaher masoudYoutube imugenelimitedEmma earl freddy crossleyLeslie chongImugene limited contacts

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs

MaxCyte Signs Strategic Platform License with Imugene to Advance their Cancer Immunotherapy Programs
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesWestern australiaNew south walesNorth carolinaChris welshYoutube imugenelimitedMary jane elliottMatt wrightLeslie chongMaher masoudPanmure gordonEmma earl freddy crossleyRupert deardenDavid deuchlerMaxcyte inc